4XC1 Stock Overview
A clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KalVista Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.65 |
| 52 Week High | US$20.20 |
| 52 Week Low | US$7.30 |
| Beta | 0.91 |
| 11 Month Change | -22.07% |
| 3 Month Change | -24.78% |
| 1 Year Change | 17.69% |
| 33 Year Change | -32.42% |
| 5 Year Change | -33.46% |
| Change since IPO | 7.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4XC1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -0.7% | 0.2% |
| 1Y | 17.7% | -17.2% | 8.5% |
Return vs Industry: 4XC1 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 4XC1 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 4XC1 volatility | |
|---|---|
| 4XC1 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 4XC1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4XC1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 150 | Ben Palleiko | www.kalvista.com |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial.
KalVista Pharmaceuticals, Inc. Fundamentals Summary
| 4XC1 fundamental statistics | |
|---|---|
| Market cap | €479.71m |
| Earnings (TTM) | -€136.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs 4XC1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4XC1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$93.47m |
| Gross Profit | -US$93.47m |
| Other Expenses | US$48.30m |
| Earnings | -US$141.77m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4XC1 perform over the long term?
See historical performance and comparison